{"symbol": "SRPT", "companyName": "Sarepta Therapeutics Inc", "exchange": "NASDAQ/NGS (GLOBAL SELECT MARKET)", "industry": "Pharmaceutical Preparation Manufacturing ", "website": "www.sareptatherapeutics.com", "description": "Sarepta Therapeutics Inc. is leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with raredisease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company's programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing.", "CEO": "Douglas Ingram", "securityName": "Sarepta Therapeutics Inc", "issueType": "cs", "sector": "Manufacturing", "primarySicCode": 2834, "employees": 866, "tags": ["Health Technology", "Biotechnology", "Manufacturing", "Pharmaceutical Preparation Manufacturing "], "address": "215 1st St Ste 415", "address2": null, "state": "Massachusetts", "city": "Cambridge", "zip": "02142-1213", "country": "US", "phone": "16172744000"}